Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this study is to learn if a suprachoroidal triamcinolone injection can treat vision-threatening swelling in the center of the retina (macular edema) caused by non-infectious uveitis, especially in people who did not improve after a standard steroid injection around the eye (sub-Tenon injection).
The main questions it aims to answer are:
Does vision improve on the eye chart after the injection?
Does the injection lower retinal swelling (reduction in thickness) within 3 months?
Participants will:
Have a pre-treatment check (vision test, slit-lamp exam, and a retinal scan called OCT).
Receive one suprachoroidal triamcinolone injection under anesthetics drops in a sterile setting (operating room) with standard monitoring.
Return for visits about 1 month and 3 months after treatment for repeat vision tests, and OCT scans.
Contact the clinic if they notice pain, redness, new floaters, or worsening vision.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Suprachoroidal Triamcinolone treatment arm | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Suprachoroidal triamcinolone acetonide injection | Drug | For suprachoroidal injection, we developed a custom-made delivery system to access the potential suprachoroidal space. A 1 mL tuberculin syringe fitted with a 27-gauge needle was prepared, and a plastic sleeve from a 24-26 G IV cannula was placed over the needle as a spacer to control penetration depth. |
| Measure | Description | Time Frame |
|---|---|---|
| Visual acuity improvement | visual acuity improvement was defined as a gain of two or more lines in visual acuity or a reduction in logMAR values | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Central Macular Thickness | A reduction in central macular thickness (CMT) exceeding 20%. | 3 Months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mohammed Suhail Al-Salam | Contact | +964 790 183 6367 | mohammedsuhail@uomustansiriyah.edu.iq |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ibn Al-Haitham Eye Teaching Hospital | Recruiting | Baghdad | 10064 | Iraq |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jun 1, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Aug 21, 2025 |
| Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D008269 | Macular Edema |
| ID | Term |
|---|---|
| D008268 | Macular Degeneration |
| D012162 | Retinal Degeneration |
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided